TOKYO -- Japanese drugmaker Daiichi Sankyo will spend 1.5 trillion yen ($13.6 billion) on new cancer treatments under its five-year plan through March 2026, accelerating its push to develop potential blockbuster drugs.
"We are making great headway in our cancer business," President and CEO Sunao Manabe said at an online news conference Monday to announce the new plan. "We are on the path to becoming a global drug developer with an edge in cancer treatments."
